ABT-737

A BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; shows no inhibition against Mcl-1, Bcl-B or Bfl-1; induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway; exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models.Ovarian Cancer Phase 2 Clinical.

Product Specifications

CAS Number

852808-04-9

Product Name Alternative

ABT737 | ABT 737

Purity

>98% (HPLC)

Solubility

10 mM in DMSO

Smiles

O=C (NS (=O) (C1=CC=C (N[C@H] (CCN (C) C) CSC2=CC=CC=C2) C ([N+] ([O-]) =O) =C1) =O) C3=CC=C (N4CCN (CC5=CC=CC=C5C6=CC=C (Cl) C=C6) CC4) C=C3

Molecular Formula

C42H45ClN6O5S2

Molecular Weight

813.4269

Storage Conditions

Storage temperature: -20°C. Stability: ≥ 2 years

Notes

For research use only.

Other Product Names

Benzamide, 4-[4-[ (4'-chloro[1,1'-biphenyl]-2-yl) methyl]-1-piperazinyl]-N-[[4-[[ (1R) -3- (dimethylamino) -1-[ (phenylthio) methyl]propyl]amino]-3-nitrophenyl]sulfonyl]-